 Affimed recently reported their Q1 earnings that revealed a solid beat on EPS and revenue. However, the company also announced that Genentech has stopped one of their partnered programs. Following the Genentech announcement, the share price has been under pressure. I believe the market is overreacting, which could provide an opportunity to buy. 